FibroBiologics Inc., a clinical-stage biotechnology company, has announced the successful completion of its third $5 million tranche as part of a $25 million Standby Equity Purchase Agreement with Yorkville Advisors Global, LP. This agreement allows the company to sell up to $25 million of its common stock over two years. The funds will be used for general corporate purposes, including advancing research and development programs and supporting a Phase 1/2 clinical trial for diabetic foot ulcers set to commence in late 2025. With over 275 patents, FibroBiologics focuses on developing therapeutics for chronic diseases using fibroblasts and fibroblast-derived materials. The recent funding marks a significant step in the company's expansion efforts.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。